OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
FOCUS Trial: Validation of MammaPrint for ≥ 70yrs w/ UltraLow risk of distant recurrence
J Geriatr Oncol. 2022 Nov;13(8):1172-1177 Authors: Noordhoek et al.
Read MoreI-SPY2: ImPrint immune signature identifies ESBC patients who benefit from PD1 checkpoint inhibition
ASCO 2022, Poster #514 Authors: Kuilman et al.
Read MoreBudget impact analysis for the Health Care Package by using MammaPrint in Belgium
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure K (1), Van der Meijden C (1), Klinkhamer J (1) , Cusumano P (2). 1- Medical & Clinical Affairs, Agendia NV., Amsterdam, Netherlands, 2 - Breast Clinic, Centre Hospitalier Chrétien, Liège, Belgium Background & Objective Gene expression profiling (GEP) tests, Read More
Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors Esther Schuler(1), Sahra Uygun(2), Lorenza Mittempergher(3), Darina Pronin(3), Sammy Mee(2), Simon Bao(2), Tyson Cavness(2), Anke Witteveen(3), and Annuska Glas(3) 1. Zotz|Klimas, MVZ Düsseldorf-Centrum GbR, Germany 2. Agendia Inc., Irvine, CA 3. Agendia NV., Amsterdam, Netherlands Background The MammaPrint® 70-gene signature (70GS) risk Read More
Durvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989–998, 2021 Authors: Pusztai et al.
Read MoreGene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer
PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Kanter Marks1,2, Heather M. Kling3, Josien Haan4, William Audeh3, FLEX Investigators Group5 Background Lymphovascular invasion (LVI), the passage of carcinoma cells through lymphatic and blood vessels, is an important early step in metastasis; however, LVI is excluded from most breast Read More
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC
Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Miranda Kleijn, Heather Kling, Amy M. Truitt, Darina Proni, Christine Finn, William Audeh, Bastiaan van der Baan, FLEX Investigators’ Group Background: The personalized management of early-stage breast cancers is enhanced by the ability of genomic signatures to stratify tumors into Read More
